Follistatin vs Mod GRF 1-29
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Follistatin
Follistatin is a glycoprotein that inhibits myostatin, the protein responsible for limiting muscle growth. By blocking myostatin, follistatin can theoretically allow for increased muscle development beyond natural limits.
Full details →Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →Side-by-Side Comparison
| Aspect | Follistatin | Mod GRF 1-29 |
|---|---|---|
| Mechanism | Binds to and neutralizes myostatin and activin, both of which are negative regulators of muscle mass. This removes the natural brake on muscle growth, allowing for enhanced hypertrophy. | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. |
| Typical Dosage | Research protocols typically use 100-300mcg daily, though optimal dosing is not well established. Gene therapy approaches have also been studied. | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. |
| Administration | Subcutaneous injection. Different isoforms exist (FS344, FS315) with varying properties. Requires careful sourcing due to complexity. | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. |
| Side Effects | Limited human data. Theoretical concerns about effects on other organs where activin signaling is important. | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. |
| Best For |
What They Have in Common
Both Follistatin and Mod GRF 1-29 are commonly used for: